WealthShield Partners’s Teva Pharmaceuticals TEVA Stock Holding History

WealthShield Partners’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-15,830	Closed	-$477K	–	587
2026 Q1	$477K	Sell	15,830 -166	-1%	-$5.34K	0.05%	246
2025 Q4	$499K	Hold	15,996	–	–	0.06%	243
2025 Q3	$323K	Hold	15,996	–	–	0.04%	276
2025 Q2	$268K	Buy	15,996 +996	+7%	+$16.1K	0.03%	290
2025 Q1	$231K	Hold	15,000	–	–	0.03%	295
2024 Q4	$331K	Hold	15,000	–	–	0.05%	238
2024 Q3	$270K	Hold	15,000	–	–	0.04%	256
2024 Q2	$244K	Buy	+15,000	New	+$231K	0.04%	256
2022 Q2	–	Sell	-17,996	Closed	-$169K	–	332
2022 Q1	$169K	Buy	+17,996	New	+$150K	0.03%	321

Other funds holding TEVA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

HIIFS

Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return

WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return

MIFH

Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

LIM

Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

WealthShield Partners's TEVA Position: Q2 2026 in Review

WealthShield Partners sold out of Teva Pharmaceuticals (TEVA) in Q2 2026, closing a stake of 15,830 shares — an estimated $477K sold.

WealthShield Partners first reported a position in TEVA in Q1 2022 and held it in 9 quarters. The position peaked at $499K in Q4 2025. 673 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

WealthShield Partners reported no remaining Teva Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
WealthShield Partners sold 15,830 Teva Pharmaceuticals shares in Q2 2026, an estimated $477K.
WealthShield Partners first reported a position in Teva Pharmaceuticals in Q1 2022 and held it in 9 quarters.
WealthShield Partners's Teva Pharmaceuticals position peaked at $499K in Q4 2025.
673 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on WealthShield Partners's 13F filing for Q2 2026, filed 12 Aug 2026.